StreetAlpha.app
Home › Stocks › ZNTL

Zentalis Pharmaceuticals, Inc. (ZNTL)

Healthcare
$1.36
▲ +0.00%
LAST CLOSE · NOV 20

Zentalis Pharmaceuticals develops azenosertib, an experimental oral cancer drug for ovarian cancer and other tumors. It last closed at $1.36 on Nov 20, up 0.00% on the day. The next earnings report for ZNTL is expected around Thu, Mar 25, 2027, after the close. For the quarter ended Sep 2026, ZNTL reported EPS of -$0.34. Over its last 8 reports the stock moved an average of 7.4% the session after earnings. Over the last 12 months ZNTL insiders bought $22.9M of stock on the open market and sold $10.1M, according to SEC Form 4 filings.

AI Auto Pilots
Is ZNTL in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold ZNTL.

Key Stats

Last 12 months
Results
Net income
−$141.7M
EPS (diluted)
−$1.90
Free cash flow
−$133.9M
Valuation
Market cap
$133.6M
98.3M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$24.0M
At Sep 30
Shareholder equity
$204.9M
Shares outstanding
98.3M
At Nov 4
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2022: $0$0FY2022FY2023: $0$0FY2023FY2024: $67.4M$67.4MFY2024FY2025: $0$0FY2025

From ZNTL's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Next report
Mar 25
Estimated date · After the close
Reported EPS
-$0.34
Quarter ended Sep 2026
Year ago EPS
-$0.37
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.66Dec '24Mar 2025: -$0.67Mar '25Jun 2025: -$0.37Jun '25Sep 2025: -$0.37Sep '25Dec 2025: -$0.49Dec '25Mar 2026: -$0.50Mar '26Jun 2026: -$0.59Jun '26Sep 2026: -$0.34Sep '26Latest -$0.34
Revenue by quarter
Dec 2024: $26.9MDec '24Mar 2025: $0Mar '25Jun 2025: $0Jun '25Sep 2025: $0Sep '25Dec 2025: $0Dec '25Latest $0
How ZNTL moved after its last 8 reports
Average move the session after a report ±7.4%
Nov 9, 2026After the close+3.5%
Aug 6, 2026After the close−15.6%
May 12, 2026After the close0.0%
Mar 26, 2026After the close−21.4%
Nov 10, 2025After the close+6.1%
Aug 6, 2025After the close+5.1%
May 14, 2025After the close+5.9%
Mar 26, 2025After the close+1.7%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on ZNTLStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on ZNTL
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on ZNTL

Technical Analysis

ZNTL · as of the Nov 20 close · updated each morning
Downtrend, oversold

The stock is 28% below its 20 day and 69% below its 50 day average. It is 148% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 24), oversold. The nearest support is the Pivot S1 at $1.29, and the nearest resistance the Pivot at $1.40.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 13.2%/day
Key levels
$6.9552 week high+411.0%
$3.37200 day average+147.8%
$3.30100 day average+142.6%
$2.3050 day average+69.1%
$1.98Swing high (Nov 11)+45.6%
$1.7420 day average+27.9%
$1.46Pivot R1+7.4%
$1.40Pivot+2.9%
$1.36Last close
$1.29Pivot S1−5.1%
$1.2852 week low−5.9%
Indicators
RSI (14)23.93Oversold below 30Oversold
MACD-0.27Below its signal lineBearish
Stochastic5.8Near the bottom of its rangeOversold
ADX (14)49.0Strong downtrend
Williams %R-91.2Oversold below −80, overbought above −20Oversold
CCI (20)-147.8Oversold below −100, overbought above 100Oversold
Rate of change−20.9%Change over 10 sessionsBearish
ATR (14)$0.18Typical daily range, 13.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ZNTL

What happened before

See how ZNTL did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow ZNTL usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How ZNTL has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for ZNTLHow many large options trades hit ZNTL, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

ZNTL Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲72 buying vs 44 selling
  • ▲Held by funds +20.8 pts
  • ▲Funds holding +12
  • ▼Superinvestors: 1 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding128116+10.3%
In funds' top 1045−20.0%
Held by funds69.2%48.4%+20.8 pts
New / increased26 / 4634 / 30+12.5%
Reduced / sold out30 / 1432 / 18−12.0%
Put/call ratio0.000.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ZNTL institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

ZNTL Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$22.9M2 buys · 2 insiders
Sold$10.1M5 sales · 4 insiders
1% of the selling was under pre-arranged trading plans.
2025-12 bought $7.8M2025-12 sold $10.0M2026-02 sold $135K2026-08 bought $15.2MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Aug 14Walters Group10% ownerBuy4,335,000$3.50$15.2M
Feb 10Vincent VultaggioPAO and PFOSale plan40,224$2.42$98K
Feb 9Julia Marie EastlandCEO & PresidentSale8,755$2.43$21K
Feb 9Ingmar BrunsChief Medical OfficerSale3,297$2.43$8K
Feb 3Vincent VultaggioPAO and PFOSale plan3,096$2.54$8K
Dec 31, 2025William Thurman Walters10% ownerBuy6,459,973$1.20$7.8M
Every insider buy and sale for ZNTL over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See ZNTL insider trades →

From SEC Form 4 filings by ZNTL's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ZNTL is in one of them and how their past ZNTL trades turned out.

ZNTL in the AI portfolios
Loading…

ZNTL News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ZNTL in an article yet. Here's the latest on the wider market.

ZNTL in the news

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals is a drug developer based in San Diego, California. Its main focus is azenosertib, an experimental oral medicine that works by blocking a cell protein called WEE1. The drug is being developed for patients with ovarian cancer and possibly other tumor types. The company is testing it in clinical trials, with its current focus on patients with platinum-resistant ovarian cancer whose tumors show high levels of Cyclin E1 protein.

Headquarters
San Diego, CA